A new drug from Biogen called BIIB080 has shown promising early results in reducing levels of tau protein, a toxic protein linked to Alzheimer's disease. A Phase Ib trial found that the drug reduced tau

Liebe Steemians, liebe Anleger und Börsenfreunde, am letzten Wochenende waren wir bei Freunden im Salzburger Land unterwegs und trafen uns am Abend mit weiteren Bekannten am Wallersee. Es stellte sich

Biogen/Eisai to present updated subgroup analyses on their Phase 2 study looking at their Alzheimer's medicine, BAN2401. This antibody binds to amyloid beta protofibrils, reducing plaques in the brain.

Biogen could potentially set up here for a rebound higher from very oversold conditions.

A fresh report has been added to the wide database of Market Research Hub (MRH) titled “Global Bleeding Disorders Treatment Sales Market Research Report (2018-2025)” which provides an outlook of current